The CSL Parkville facility has undergone several phases of expansion since 1997 when it was first opened. The production facilities have been expanded three times.
The most recent phase of construction was from 2001 to 2002 when a major expansion of the company’s influenza vaccine production facility was completed. This doubled previous production capacity in line with the new demand for CSL’s vaccine products for the home market and the international market.
This new capacity was developed to meet increased influenza vaccine requirements and the company has already signed a major contract to supply influenza vaccine (FLUVAX) to countries in the Northern Hemisphere.
The influenza vaccine is the company’s main revenue source and by optimising production capacity to supply both northern and southern-hemisphere winter requirements, the plant is in full production all year around.
With the advent of H5N1 avian flu in Asia and worldwide, vaccines are in even greater demand and the company aims to capitalise on its production capacity.
In late 2005, CSL signed a contract with Merck & Co to supply Iscomatrix adjuvant for Merck’s pipeline of investigational vaccine products. Iscomatrix adjuvant is a phospholipid-cholesterol formulation containing a purified saponin from the Quillaj saponaria tree. The adjuvant is used to enhance immune stimulation when vaccines are administered. These kinds of adjuvant are a CSL speciality with all of its experience in producing and marketing its own vaccines.
CSL completed an A$10.8m upgrade of its insulin production facility in Parkville in 1999. The upgrade was carried out to provide a pilot-scale good manufacturing practice (GMP) compliant facility for the production of experimental and clinical scale biopharmaceuticals. The contractor responsible for the design, construction, procurement and management of the project was Hooker Cockram.
Instigated in 1998, the project was completed in under a year and has a floor space of 980m². The upgraded facility included new Class 100 cleanrooms, interlocked pass-throughs, extensive fume hood facilities, a new water for injection (WFI) production plant, autoclaves and a programmable logic control automation system. Hooker Cockram undertook most of the validation and commissioning requirements, including the development of new protocols and computer validation.
In 1999, CSL opened a new A$14m (US$8.3m) biotech plant in Parkville, Victoria. The plant manufactures a variety of products, including vaccines against a variety of organisms such as Helicobactor pylori, which is implicated as a cause of peptic ulcers and stomach cancers.
The new plant is contained within a three-storey building, which is half owned by CSL. The company develops, manufactures, markets and distributes pharmaceutical products for humans and animals. One of the company’s most successful products on the veterinary side is a vaccine for Q-fever, a major problem in Australia for cattle farmers.
The facility has enabled the production of large quantities of recombinant proteins under stringent standards for research and commercial markets. Through the new capacity, the plant is more than capable of producing products such as genetically engineered vaccines and other biologicals on a contract basis for evaluation in clinical studies and is able to produce quantities of materials for large-scale clinical studies in many countries.
This facility allows CSL to have independence so that clinical trial drugs do not have to be manufactured overseas and can be kept in-house. CSL is also using the facility to research into the fermentation of various genetically engineered bacteria (E. coli and of mammalian origin) and yeasts to produce biologically active proteins (monoclonal antibodies and other therapeutic compounds) to expand its product range.
CSL has the distinction that it has been able to fully fund all of its research projects to date. It is the largest investor in pharmaceutical research and development (R&D) in Australia and is supported by the federal government whose schemes include a 125% tax deduction for R&D) (formerly 150%) and the Factor (f) scheme, which compensates pharmaceutical companies for selling drugs in Australia at less than world market prices if they undertake R&D locally.
These subsidies have allowed a structured and focused push of home-grown science into commercialisation for Australia. CSL is the country’s largest and most successful biotech company.
The company was formerly the Commonwealth Serum Laboratories Commission (hence the name CSL), established in 1916 as part of the quarantine division of the Commonwealth Department of Trade and Customs. It moved to the Department of Health in 1921. The commission became a corporate body under the Commonwealth Serum Laboratories Act 1961.
CSL was incorporated in 1991, and in 1992 the company signed an agreement with Merck Sharp & Dohme (Australia) and Merck & Co to develop combination vaccines for children in Australia, New Zealand and the Asia-Pacific (APAC) region.
In 1993, CSL entered a ten-year agreement with the commonwealth to manufacture and supply a range of plasma-derived products for Australia. It went on to sign a ten-year agreement with the Australian Red Cross to distribute fractionised plasma products and acquired a majority interest in Iscotec, a Swedish company with global rights to commercialise a vaccine response enhancer.
It also acquired the assets and business of JRH Biosciences and was appointed exclusive Australian distributor for the products of Ortho Diagnostic Systems (US).
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…